Clinical trials listed for ITP are a starting point for discussion with a healthcare professional. Be sure you understand all the implications of the proposed treatment by reading the informed consent very carefully and speaking with your doctor before enrolling in a clinical trial.
What are Clinical Trials?
Clinical Trials are controlled patient studies that must be performed before a new drug or treatment is approved by the Food and Drug Administration (FDA) in the United States and similar organizations in other countries. Clinical trials are also completed after a drug or treatment is approved to document the effectiveness of the treatment, or to gain approval to use the drug or therapy for a different disease or age group.
There are three main phases to clinical trials, completed in sequence. A Phase I study tests the safety and side effects of the drug. A Phase II study is initiated to determine the efficacy of the drug, to see if it works as anticipated. And, a Phase III study tests the efficacy of drug or treatment and documents the side effects in a large population of volunteers.
Finding a Clinical Trial
The best way to find the latest information on clinical trials is by visiting ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. Pharmaceutical companies and researchers update this site frequently to ensure it contains the most comprehensive and up-to-date clinical trial listings. The database features an easy-to-use search facility and detailed guidance for patients and industry.
Featured Clinical Trials
RUBY-4 is a phase 1b/2 clinical study of the safety and potential effectiveness of povetacicept in patients whose ITP is not well controlled with their current medication(s).
- Povetacicept (pō-və-tak’-i-sept) is designed to block two molecules, BAFF and APRIL, that are important for the function and survival of cells that produce harmful antibodies in patients with ITP.
- All participants who enroll in RUBY-4 will receive treatment with povetacicept, which will be given as an injection under the skin once a month for 6 months, with potential for a 6-month extension.
- Povetacicept is provided at no cost, and reimbursement may be available for study-related expenses such as travel.
- The study is currently enrolling patients in AZ, CA, CO, FL, GA, NJ, NY, TX and in Australia, Canada and Turkey.
To see if you may be a candidate for RUBY-4 participation please go to: www.ruby4clinicalstudy.com
List of Clinical Trials
- Clinical Trials Actively Recruiting in the USA
- Clinical Trials Actively Recruiting in Canada
- Clinical Trials Actively Recruiting Internationally
- Clinical Trials Active But Not Recruiting
- Completed Clinical Trials
- Clinical Trials for Other Platelet Disorders
- Clinical Trials Not Yet Recruiting
Please contact PDSA if you find missing or incorrect information regarding any of the clinical trials listed.